introduction
In many parts of Asia, including Southern China and Southeast Asia, nasopharyngeal carcinoma (NPC) is the most common head and neck cancer, with an incidence between 15 and 50 cases per 100 000. The primary treatment for non-metastatic NPC is a course of radical radiotherapy (RT) in early stage and concurrent cisplatin-RT in locally advanced stage [1] . Recent advances in tumor imaging and RT delivery have contributed to improvement in local control of this disease. However, patients with advanced disease (International Union Against Cancer stages III and IV) have significant rates of local relapse and distant metastasis after primary treatment. For patients relapsed with distant metastasis, the prognosis is poor, with reported median survival times ranging from only 5 to 11 months [2] .
A wide range of chemotherapeutic agents has been used in the treatment of locally recurrent or metastatic NPC. Although the activity of platinum-based chemotherapy in patients with recurrent or metastatic NPC is high, with response rates >50%, the duration of response and survival time are limited and palliative second-line chemotherapy is only reserved for good performance patients [3] . A small number of publications have reported the outcome of treatments given to recurrent or metastatic NPC patients who progressed after palliative platinum-based chemotherapy [4, 5] . Patients with recurrent or metastatic NPC have few therapeutic options once they have progressed on platinum-based chemotherapy. There is therefore a clear unmet need for new anticancer agents in this indication. Targeted biologics are now becoming available for clinical uses, which offer the promise of new treatment options for this patient group [6] .
Angiogenesis is essential for tumor growth and metastases, and one of the key angiogenic factors is vascular endothelial growth factor (VEGF) [7] . In NPC, expression of VEGF was demonstrated to have significant association with angiogenesis and lymph node metastases [8] , as well as distant metastases [9] . Our group has previously demonstrated that overexpression of VEGF was present in >60% of clinical biopsies of NPC, which was coexpressed with hypoxia markers original article HIF-1a and CA IX, and associated with poor outcome after radiation treatment [10] . Other studies also highlighted the significant role of tumor angiogenesis in NPC [11] [12] [13] [14] [15] [16] . In preclinical studies, antiangiogenesis treatment has already demonstrated promising results in NPC [12, 17, 18] . Sunitinib malate (Pfizer, New York, NY) is an orally administered small molecule that inhibits the tyrosine kinase activities of VEGF receptor (VEGFR1-3), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (KIT), fms-like tyrosine kinase receptor-3 and rearranged during transfection. Sunitinib exhibits direct antitumor activity against tumor cells dependent on those receptor signaling for proliferation/survival [19] . Sunitinib also has antiangiogenic activity through its inhibition of VEGFR and PDGFR signaling [20] . Our own preclinical study has demonstrated potent single-agent activity of sunitinib in NPC cell lines and xenograft models [21] .
The most commonly tested regimen of sunitinib is a 6-week cycle comprising daily treatment for 4 weeks followed by a 2-week rest period (schedule 4/2). Recent reports suggested that a continuous daily regimen of sunitinib may provide the advantage of maintaining sustained antitumor activity and preventing tumor regrowth during the 2-week off-treatment period [22, 23] . This phase II clinical trial aimed to evaluate the activity and safety of sunitinib administered in a continuous once-daily dosing schedule as second-line single-agent treatment in patients with recurrent or metastatic NPC.
patients and methods

patients
Patients aged ‡18 years with histologically proven NPC, recurrent or metastatic and evidence of measurable disease based on RECIST [24] were eligible. Additional eligibility criteria included disease progressed after at least one line of prior platinum-based chemotherapy and not amenable to potentially curative RT or surgery; Eastern Cooperative Oncology Group performance zero to two and adequate bone marrow, renal and hepatic reserve. Patients were excluded if they had history of hemorrhage of grade 3 or higher within 4 weeks of starting study treatment; second malignancy within the last 3 years; central nervous system metastases; uncontrolled hypertension; significant cardiovascular disease including myocardial infarction/unstable angina or congestive heart failure within 12 months; ongoing cardiac dysrhythmias or prolongation of the QTc interval to >450 ms for males or >470 ms for females; treatment with anticonvulsant agents or therapeutic doses of warfarin; inability to swallow oral medications or presence of active inflammatory bowel disease, partial or complete bowel obstruction or chronic diarrhea and pregnancy or breastfeeding.
The trial was approved by the Clinical Research Ethics Committee of The Chinese University of Hong Kong and conducted in accordance with the Declaration of Helsinki (2000). All patients provided written informed consent before study enrollment.
study procedures
Eligible patients received sunitinib at a starting dose of 37.5 mg once daily for four consecutive weeks. Treatment cycles were repeated every 4 weeks. There would be no treatment break between cycles unless in the event of grade 3 or higher toxicity. Patients were evaluated biweekly for serial laboratory testing and clinical assessment. 12-lead electrocardiograms were done at baseline, on day 1 of cycle 2 and at end of treatment or study withdrawal. Adverse events (AE) were graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 3.0. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent. Dose reduction (to 25 mg daily and then to 12.5 mg daily) was allowed in case of recurrent toxicity of grade 3 or higher. Computed tomography (CT) or magnetic resonance imaging (MRI) were carried out at screening and repeated every three cycles. Objective tumor response was assessed using RECIST. Patients were followed after treatment discontinuation for survival status.
statistical analysis
The primary end points were clinical benefit rate (CBR) and time to progression (TTP). Secondary end points included overall response rate, toxicity, progression-free survival (PFS) and overall survival (OS). CBR was defined as the percentage of patients with confirmed complete response, partial response (PR) or stable disease (SD) lasting for at least 12 weeks on study according to RECIST. TTP was defined as the time from start of study treatment to first documentation of objective tumor progression. Time-toevent data were summarized using the Kaplan-Meier method. In an exploratory analysis, the association between hemorrhagic events and clinical risk factors were tested with Fisher's exact test. The statistical analysis was conducted with SAS 8.0 (SAS Institute Inc., Cary, NC).
The sample size was calculated based on CBR (nonprogression rate) using Simon's Minimax two-stage phase II design [25] . We considered the study drug to be inactive if the nonprogression rate is at most 50% and considered the study drug as active if the nonprogression rate is at least 70%. Therefore, assuming P0 = 0.50, P1= 0.70 and the type I error of 0.05 with power of 80%, we would recruit 23 patients in stage I. If we observed 12 or less nonprogression, we would stop the study and conclude the study drug as inactive, otherwise we would proceed to stage II and accrue an additional 14 patients. If £23 of the 37 patients were nonprogressors, the drug would be deemed inactive.
results
patient and treatment
Fourteen patients were enrolled from July 2007 to April 2008. Recruitment was stopped after the death of two patients with hemorrhagic events. The baseline patient characteristics are summarized in Table 1 . All patients received prior definitive curative-intent RT to nasopharynx and neck, and nine patients also received concurrent chemotherapy with the radical RT. Two, five, four and three patients had received one, two, three and four lines of prior chemotherapy, respectively, after recurrence.
Patient received a median of three cycles (range 1-24) of sunitinib. All patients required dose interruption. Eight (57%) patients had dose reduced to 25 mg daily and two (14%) patients required further dose reduction to 12.5 mg daily. The reasons for dose reduction were for nonhematological toxicity in eight patients and hematological toxicity in two patients. The primary reason for treatment discontinuation (n = 13) was disease progression (n = 9), AE (n = 2) and death (n = 2). safety AE encountered during study that were possibly related to the administration of sunitinib are depicted in Table 2 . Hemorrhagic events (all grades) occurred in nine patients (64%), all from bleeding sources in the upper aerodigestive tract, including epistaxis in six patients, hemoptyses in three patients and hematemesis in two patients (Table 3) . Nine patients had pulmonary metastases (Table 1) , and three of them developed hemoptyses during sunitinib treatment (Table 3) . Two patients who had received prior palliative RT to thorax (mediastinum or thoracic spine) developed hemoptyses compared with 1 of 12 patients who did not received prior RT to thorax developed hemoptyses, suggesting an association between prior RT to thorax and hemoptyses (P = 0.03, Fisher's exact test). Two patients with local recurrent disease developed grade 5 epistaxis/hematemesis within first 4 weeks of sunitinib treatment. In both patients, the local recurrent tumors had extended from the nasopharynx posterolaterally to invade the parapharyngeal space and completely encase the internal carotid artery on the pretreatment MRI scan (Figure 1 ). In contrast, another two patients with local recurrence never developed any symptoms of bleeding from the upper aerodigestive tract during sunitinib treatment. In these two patients (who did not bleed), the local recurrent tumor in the nasopharynx had extended also to the parapharyngeal space, but the tumor had not extended any further posterolaterally into the carotid space (poststyloid space) to involve the wall of internal carotid artery.
efficacy
Of the 10 patients who had completed at least one postbaseline radiological assessment, tumor shrinkage was noted in 5 patients. Response could not be evaluated in the other four patients since one died of hemorrhage, one withdrew consent because of toxicity and two had clinical deterioration before radiological assessment.
By RECIST criteria, one patient achieved a confirmed PR for duration of 5.6 months. A further three patients had stabilization of disease lasting for at least 12 weeks, giving a CBR of 28.6% (4/14, 95% CI 4.4% to 52.7%) in the total intent-to-treat population. Three patients received sunitinib for >12 cycles. The serial CT scan appearance of the target tumor lesions in one of these patients are shown in Figure 2 . At the last follow-up, one patient was still continuing on sunitinib treatment with SD and good symptom control after 24 cycles.
After a median follow-up of 23.1 months, the median TTP was 4.4 months (95% CI 2.8-9.4), the median PFS was 3.5 months (95% CI 2.5-9.4) and the median OS was 10.5 months (95% CI 7.2-20.7). The actuarial 1-year OS rate was 35.7%.
discussion
Angiogenesis is a key pathway involved in tumor growth and metastases. In the past few years, several new agents developed as angiogenesis inhibitors have been targeting the VEGFR. At least four such agents have already obtained US Food and Drug administration (FDA) approval for clinical use and many others have entered into clinical trials. Thus, an increase in their use is expected in the near future. The FDA-approved agents include the monoclonal antibody against VEGF bevacizumab (Genentech, South San Francisco, CA) and the VEGFR tyrosine kinase inhibitors sunitinib (Pfizer), sorafenib (Bayer Pharmaceuticals, West Haven, CT) and pazopanib (GlaxoSmithKline, London, UK). These agents do not show the typical side-effects of cytotoxic chemotherapy. However, a new pattern of toxicity has been observed, including hemorrhage, thrombosis, hypertension, proteinuria, bowel perforation, impaired wound healing, cardiac impairment, hypothyroidism and reversible posterior leukoencephalopathy [26] [27] [28] [29] [30] [31] [32] .
To our knowledge, this is the first clinical study to explore the activity of sunitinib in patients with recurrent or metastatic NPC. All patients were pretreated with radiation and received multiple prior chemotherapy. Although the types of toxic effects reported here are consistent with those seen in previous studies of single-agent sunitinib in other cancer types, with the most common toxic effects being fatigue, dermatological and gastrointestinal side-effects, both the incidence and severity of hemorrhagic events were much more pronounced. However, the single-arm study design without a control group and the original article Annals of Oncology early suspension of the trial make it difficult to determine true incidence of hemorrhagic events during antiangiogenesis therapy in NPC. A recent retrospective report highlighted that frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy (sorafenib or sunitinib) in advanced renal cell carcinoma and suggested that the initial grade 3 or 4 AE presented in the literature appeared to have been underreported [33] . In our study, we observed a similar high incidence of nonhematological toxic effects that mandated dose interruptions and/or dose reductions. We hypothesized that the preexisting late radiation toxicity prevalent in NPC who received prior high-dose radiation (such as chronic xerostomia) could have predisposed NPC patients to development of local AE in the upper aerodigestive tract (odynophagia, glossitis or mucositis). We also observed a relative high incidence of hypothyroidism (which was almost universal in patients who took sunitinib beyond 3 months). The prior exposure of highdose radiation to neck could have predisposed NPC patients to subsequent development hypothyroidism during sunitinib treatment. We suggest that monitoring of thyroid function is mandatory during sunitinib treatment in patients who received prior radiation to the neck.
Previous studies combining VEGF/VEGFR inhibition and radiation have reported greater than additive effect in a variety of tumor model systems in vivo. The mechanisms of interaction between antiangiogenic agents and ionizing radiation are complex and may involve multiple interactions between tumor stroma, vasculature and the tumor cells [34] . However, the role of VEGF in the repair of chronic or late radiation damage remains unclear. Radiation damaged vessels were shown to be more sensitive to VEGFR inhibition in tumor model system [35] . Clinically, increased risk of ischemic bowel complications during treatment with bevacizumab after previous pelvic irradiation has been reported [36] . Fatal bowel perforation within the area of irradiation occurred in a patient receiving sorafenib, suggesting its potential as radiosensitizer [37] . In a phase I trial of bevacizumab with concurrent RT and capecitabine in locally advanced pancreatic cancer, three patients developed tumor-associated bleeding duodenal ulcers and one had a contained duodenal perforation among the first 30 patients treated. It was suggested that ulceration and bleeding in the radiation field possibly related to bevacizumab occurred when tumor involved the duodenal mucosa. No additional bleeding events occurred among the final 18 patients after patients with duodenal involvement by tumor were excluded [38] . As antiangiogenesis therapy after radiation is becoming more frequent in daily clinical practice, clinicians should be alerted to monitor for potentially serious side-effect arising from irradiated tissues.
Vascular disruption by inhibition of existing VEGF/VEGFRdependent tumor blood vessels often lead to tumor necrosis and cavitations. In studies of non-small-cell lung cancer, fatal pulmonary hemorrhages were also observed in a number of patients. All these fatal events occurred in patients with centrally located squamous cell lung cancer [39] . It is hypothesized that presence or the development of tumor cavitations, probably a sign of antitumor activity of chemotherapy and bevacizumab, underlies these events. Patients with centrally located squamous cell lung cancer are therefore currently excluded from bevacizumab treatment.
In vivo, sunitinib decreased tumor microvessel density and induced significant tumor necrosis in an NPC xenograft model [21] . In fact, tumor necrosis leading to cavitations has previously been reported patients treated in a phase I trial of sunitinib [40] . Infection in necrotic area of lung metastasis was reported in an NPC patient enrolled in the phase I trial [40] . Nasopharyngeal hemorrhage was previously reported in a phase II trial of sorafenib that enrolled patients with recurrent or metastatic squamous cell carcinoma of head and neck or NPC. However, in that study, the author attributed the bleeding event as likely related to underlying malignancy instead of antiangiogenesis treatment [41] .
In our study, two patients with local recurrence developed grade 5 hemorrhage during the first cycle of sunitinib treatment. These patients had not reported any bleeding symptoms before sunitinib treatment despite having received multiple chemotherapies. In one of the patients, significant tumor shrinkage (>60%) was noted on the MRI study carried out before the fatal hemorrhagic event (Figure 1 ). The tumor necrosis has exposed the naked internal carotid artery to the nasopharyngeal cavity. The complete encasement of the artery on MRI before therapy suggests that invasion of the arterial wall was likely and this together with the direct exposure of the artery to the nasopharyngeal cavity likely contributed to the subsequent carotid blowout syndrome with torrential hemorrhage.
The risk of bleeding with VEGFR tyrosine kinase inhibitors sunitinib and sorafenib was investigated in a recent metaanalysis of 23 trials involving a total of 6779 patients [42] . The incidence of bleeding events (all grades) was 16.7% and that of high-grade bleeding was 2.4%. The relative risk of all-grade bleeding events associated with sunitinib and sorafenib from four randomized controlled trials was 2.0 (95% CI 1.14-3.49; P = 0.015). However, the relative risk of high-grade bleeding was raised only slightly (1.16, 95% CI 0.70-1.92; P = 0.555). The authors attributed this to the small number of events recorded and possible underreporting of rare events in clinical trials, which are not usually designed to specifically address toxic events. A high incidence of hemorrhage (8/22, 36%; 10/ 17, 59%) was also reported in two phase II trial of sunitinib in head and neck cancers, of which most of the patients had also received prior RT or chemoradiotherapy [43, 44] . In a recently completed phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck conducted by the GORTEC group, a high incidence of head and neck bleedings (13/38, 34%) was also observed, of which four were fatal hemorrhages. The authors hypothesized that late toxicity 
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owing to prior radiation therapy could have contributed to the complications and proposed that patients with tumor situated within 5 mm of large blood vessels be excluded from studies of angiogenesis inhibitors [45] .
In conclusion, sunitinib demonstrated modest clinical activity in a heavily pretreated cohort of NPC patients. However, our study is underpowered to demonstrate efficacy result because of premature termination of recruitment. We also observed that sunitinib dose reductions/interruptions were frequently required in this radiation-pretreated cohort of patients despite of a lower starting dose in a continuous daily dosing. Moreover, the high incidence of high-grade hemorrhagic events from the upper aerodigestive tract, area that were within the high-dose zone of prior RT for NPC, is a cause of concern. In particular, patients with local tumor invading the carotid sheath are at high risk of fatal hemorrhage. As a safety precaution, we propose to exclude NPC patients with disease recurrence within previous radiation field and/or invading major vascular structure from future antiangiogenesis therapy.
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